Reata Pharmaceuticals

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Sudhof, Jonathan M. Graff, and J. Warren Huff in 2002 and is headquartered in Irving, TX.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Reata Pharmaceuticals reports FDA approval for SKYCLARYS but faces commercial delay

RETA's Q1 2023 earnings call highlighted the FDA approval of SKYCLARYS for FA treatment, but commercial availability is delayed due to impurity issues. The company is discontinuing bardoxolone development and focusing on neurology programs. A new non-dilutive debt facility extends the company's cash runway to 2026, presenting a positive financial outlook.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases. It offers antioxidant and inflammation-modulating drugs, as well as drugs that correct protein misfolding. The company also develops drugs for the treatment of renal, cardiovascular, and autoimmune diseases. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005.

Reata Pharmaceuticals, Inc. (RETA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Reata Pharmaceuticals, Inc. (RETA) Soars 5.3%: Is Further Upside Left in the Stock?

Reata Pharmaceuticals has enjoyed robust appreciation over the years, as the company advances two lead medicines (bardoxolone and omaveloxolone).

Reata: Big Run-Up Toward Approval

PLANO, Texas, June 07, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will participate in a virtual Fireside chat and hold 1x1 meetings at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021.

Reata Pharmaceuticals Announces Participation in The Goldman Sachs 42nd Annual Global Healthcare Conference

The FDA asks Reata (RETA) to submit a pre-NDA meeting request to discuss omaveloxolone study data and cancel its previous request for a more general Type C meeting, boosting chances of an early NDA filing.

Reata (RETA) Soars on Potential Omaveloxolone NDA Filing

The company might soon be taking a very big step toward FDA approval of an important pipeline drug.

Why Reata Pharmaceuticals Stock Is Skyrocketing Today

The U.S. Food and Drug Administration (FDA) sent a communication to Reata Pharmaceuticals Inc. (NASDAQ: RETA) on Wednesday, recommending that it submits a new request for a pre-NDA meeting. The pharmaceutical company's shares gained 20% in the morning session.

Here's why Reata Pharmaceuticals gained 20% on Wednesday

The stock price of Reata Pharmaceuticals Inc (NASDAQ: RETA) increased by over 14% pre-market. This is why it happened.

Reata Pharmaceuticals (RETA) Stock: Over 14% Increase Pre-Market Explanation

PLANO, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it received a communication from the Division of Neurology Products 1 (“Division”) of the U.S. Food and Drug Administration (“FDA”) stating that, after a preliminary review of briefing materials for an upcoming Type C meeting, a pre-NDA meeting is the most appropriate format for a discussion of the development program for omaveloxolone in Friedreich's ataxia (“FA”). The Division suggested that the Company withdraw the current meeting request for a Type C meeting and instead request a pre-NDA meeting, which the Division will grant upon receipt. The Division asked the Company to focus the new briefing package on questions, issues, and needs applicable to a pre-NDA meeting.   As requested by the FDA, the Company plans to withdraw the current request for a Type C meeting and submit a request for a pre-NDA meeting as soon as practicable.

Reata Announces that The FDA Has Asked The Company to Request a Pre-NDA Meeting for Omaveloxolone for the Treatment of Friedreich's Ataxia

CEVA

American Airlines

Blink Charging

Kirby

The major indices have all jumped as jobless claims fell to a fresh pandemic low. If you're looking for a way to play this market, the deep learning algorithms at Q.ai have crunched the data to give you a set of top shorts.

Ceva Among Top Shorts As Indices Pop Amid Low Jobless Claims

Carvana

Redfin

Amyris

Going into today, the Dow Jones continued its sell-off and fell more than 150 points while the S&P 500 lost 0.6% and the Nasdaq﻿﻿ dipped more than 1%. Our AI has identified the following stocks rated Top Short today.

AI Model Rates Redfin And Carvana Top Short Today

Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q1 2021 Results - Earnings Call Transcript

Reata (RETA) reports mixed first-quarter results wherein earnings beat estimates but sales miss the same. Stock rises.

Reata's (RETA) Q1 Earnings Beat Estimates, Revenues Miss

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 14.68% and -32.91%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Lags Revenue Estimates

ANNOUNCES FDA ACCEPTED FOR FILING REATA'S NDA OF BARDOXOLONE FOR THE TREATMENT OF PATIENTS WITH CKD CAUSED BY ALPORT SYNDROME

Reata Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs

Reata Pharmaceuticals (NASDAQ:RETA) releases its next round of earnings this Thursday, May 06. Get the latest predictions in Benzinga's essential guide to the company's Q1 earnings report.

Reata Pharmaceuticals's Earnings Outlook

PLANO, Texas, May 03, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will present and hold 1x1 meetings at the following investor conferences:

Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences

Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Reata Pharmaceuticals, Inc. (RETA) Q1 Earnings Expected to Decline

PLANO, Texas, April 28, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs pre-market on May 6, 2021.

Reata Pharmaceuticals, Inc. To Report First Quarter 2021 Financials and To Provide an Update on Development Programs on May 6, 2021

Reata Pharmaceuticals, Inc. (RETA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Reata Pharmaceuticals, Inc. (RETA): Can Its 3% Jump Turn into More Strength?

The shares of Reata Pharmaceuticals Inc (NASDAQ: RETA) have received a price target of $155 by Barclays. These are the details.

RETA Stock: $155 Target By Barclays

Approximately 30,000-60,000 Patients in the United States Are Affected With Alport Syndrome, a Life-Threatening Disease With No Approved Therapies

Reata Announces FDA Accepted for Filing the NDA for Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome

Alexion Pharma

Activision Blizzard

Baker Hughes Co

BioMarin Pharmaceutical

Esperion Therapeutics

Fate Therapeutics

Flexion Therapeutics

With the trading day about halfway over, each of the major averages had notched a solid gain and was holding just below its respective all-time high.

Alexion, Activision, Baker Hughes and More Monday Afternoon Analyst Calls

PLANO, Texas, April 15, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointments of Christy J. Oliger and Shamim Ruff to its Board of Directors, effective April 15, 2021.

Reata Announces the Appointments of Christy J. Oliger and Shamim Ruff to Its Board of Directors

PLANO, Texas, March 29, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that abstracts highlighting clinical data for bardoxolone methyl (“bardoxolone”) will be presented at two upcoming nephrology conferences including The World Congress of Nephrology 2021 being held virtually from April 15 – 19, 2021 and the 58th European Renal Association and European Dialysis and Transplant Association (“ERA-EDTA”) Congress being held from June 5 – 8, 2021 in Berlin, Germany and virtually.

Reata Pharmaceuticals Announces Presentations at Upcoming Medical Conferences

Balchem

Bio-Rad Laboratories

Benjamin Graham, the father of value investing, recommended to stick to stocks that have a current ratio of more than 2 and more working capital than long-term debt.

News for Reata Pharmaceuticals Stock (RETA)